Home > Maligne hematologie > Lymfoïde ziekten > Non-Hodgkin lymfomen (NHL) > Diffuus grootcellig B-cel NHL > DALY-2

Printen

Versie:	1.0.0
Revisie:	30-09-2022
Type:	Studie
Status:	Open
Ziektebeeld:	Diffuus grootcellig B-cel NHL
Behandellijn:	>= 2de lijn
Fase:	Fase 2
Leeftijd:	≥ 18
PI:	Dr. T. van Meerten
TC:	Margriet Dijkstra
Titel:	A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation

DALY-2

Studieprotocol

DALY-2 Protocol

ICF

DALY-2 Proefpersoneninformatie

DALY-2 Proefpersoneninformatie aanvullend onderzoek

Aanvullende documenten

DALY-2 Samenvatting

A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation

DALY-2

Hematologie Groningen